---
title: >-
  Real world characteristics and burden of patients initiating advanced systemic
  therapy in the TARGET-DERM atopic dermatitis registry.
description: >-
  Explore this publication on real-world evidence: Real world characteristics
  and burden of patients initiating advanced systemic therapy in the
  TARGET-DERM…
date: '2026-01-01'
category: Publications
tags:
  - Poster Presentation
  - Approval / Commercialization
  - Care
  - Dermatology
  - Atopic Dermatitis (AD)
  - Pharma Partner
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/poster-presentation/real-world-characteristics-and-burden-of-patients/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: real-world-characteristics-and-burden-of-patients
id: 2FyNW0z6bpDEB55L8tn5L7
contentType: article
---

## Challenge

Before prescribing advanced systemic therapies in AD, clinicians and sponsors needed real-world data on the characteristics, disease burden, and comorbidity profile of patients who newly initiate these agents in clinical practice—data that registration trials cannot provide due to their strict eligibility criteria.

## Solution

A retrospective observational cohort study using TARGET-DERM AD characterized patients initiating advanced systemic therapy (AST) for the first time, describing demographics, disease severity, comorbidities, prior treatment history, and concomitant therapy use at and after AST initiation.

## Impact

Characterizing the real-world AST initiator population—including their high comorbidity burden and persistent concomitant therapy use at 12 months—establishes the baseline context for post-authorization effectiveness studies and informs label communication for Amgen/Kyowa Kirin's AD pipeline assets.